uploads/2018/08/Premix-insulin-1.png

How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018

By

Updated

Revenue trends for premix insulins

Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY (year-over-year) growth in local currencies in the first half of 2018 to 5.2 billion Danish kroner. That included revenues of 688 million Danish kroner, 856 million Danish kroner, 1.3 billion Danish kroner, and 1.9 billion Danish kroner in the United States, Europe, AAMEO (Africa, Asia, the Middle East, and Oceania), and China, respectively.

In the first half of 2018, premix insulins witnessed a ~21% decline and a ~10% decline YoY in local currencies in the United States and Europe, respectively. However, in the AAMEO and China, premix insulins grew ~16% and ~8%, respectively, YoY in local currencies.

Novo Nordisk’s premix insulin segment generated revenues of 2.6 billion Danish kroner in the second quarter of 2018, reflecting a ~2% YoY growth in local currencies.

In Q2 2018 in the United States and Europe, the premix insulin segment generated revenues of 286 billion Danish kroner and 428 million Danish kroner, respectively. That reflected a ~27% decline and an ~11% decline, respectively, YoY in local currencies.

Article continues below advertisement

In Q2 2018 in AAMEO, China, Japan and Korea, and Latin America, premix insulins generated revenues of 713 million Danish kroner, 949 million Danish kroner, 170 million Danish kroner, and 32 million Danish kroner, respectively. That reflects an ~18% growth, a ~9% growth, a ~3% decline, and a ~20% growth, respectively, YoY in local currencies.

NovoMix revenue trends

In the first quarter of 2018, Novo Nordisk’s NovoMix generated revenues of 4.9 billion Danish kroner, reflecting a ~2% YoY decline in local currencies.

NovoMix witnessed a ~2% YoY decline in local currencies and generated revenues of 2.4 billion Danish kroner in the second quarter of 2018.

In the second quarter in the United States and Europe, NovoMix generated revenues of 286 million Danish kroner and 412 million Danish kroner, respectively. That’s a ~27% decline and a ~13% decline, respectively, YoY in local currencies.

In AAMEO, China, Japan and Korea, and Latin America in the second quarter, NovoMix generated revenues of 646 million Danish kroner, 949 million Danish kroner, 82 million Danish kroner, and 24 million Danish kroner, respectively. That reflects an ~11% growth, a ~9% growth, a ~30% decline, and a ~22% growth, respectively, YoY in local currencies.

Advertisement

More From Market Realist